|
|
|
|
|
阿德萊德，澳大利亞, 2020年4月13日 - (亞太商訊) - Leading Australian CRO Avance Clinical said there was still strong demand from Asian and US sponsors, and commended Australian sites that had risen to the challenge to deliver for Avance Clinical clients during this difficult time.
Avance Clinical is a medium-sized full-service CRO known for its nimble and collaborative approach, with more than 20-years of experience in managing early phase trials.
Avance Clinical's Chief Strategist Ben Edwards said a key factor in sponsor demand is the speed and attractive cost of running trials in Australia. In particular, they include:
- The Australian Government financial rebate of more than 40% on clinical trial spend
- No IND required for clinical trials and streamlined regulatory processes
- Advanced medical, research and scientific community, leading investigators and KOLs, and modern medical facilities
Watch video - how we work here https://www.avancecro.com/
Avance Clinical CEO Yvonne Lungershausen, who has a background in pure research, said sponsors saw the value of running studies in Australia.
"In addition, Australia is not as hard hit by the COVID-19 crisis which has meant we can work with sites to deliver studies that might otherwise be put on hold, costing time and money and causing crippling delays to drug pipelines," said Ms Lungershausen.
"We are pleased to be the Australian CRO of choice for international sponsors," she said.
"Australia's reputation for FDA compliant scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for clinical trials."
For more information about the benefits of running your next study in Australia contact us: https://www.avancecro.com/contact-us/
About Avance Clinical
Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organisations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialised patient groups. Other benefits include:
1. The Government R&D grant means more than 40% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialised patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons.
Media Contact:
media@avancecro.com
Chris Thompson
話題 Clinical Trial Results
部門 制药及生物技术, 健康与医药
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network
|
|
|
|
|
|
 |
| Avance Clinical |
|
| July 24, 2024, 08:00 HKT/SGT |
| Avance Clinical 任命亞洲區域總監，作為全球擴展計畫的一部分 |
|
| June 4, 2024, 22:46 HKT/SGT |
| 新研究發現，具有內部監管事務的CRO公司為生物技術公司節省30%的成本，縮短時間線一半，降低風險 |
|
| June 1, 2024, 06:00 HKT/SGT |
| Avance Clinical透過與Julius Clinical合作，在歐洲擴展專門的中樞神經系統、心血管代謝和罕見疾病的CRO服務 |
|
| May 9, 2024, 07:55 HKT/SGT |
| Avance Clinical 在亞太地區進一步擴張，韓國新的臨床運營 |
|
| Apr 20, 2024, 18:00 HKT/SGT |
| Avance Clinical 在4月23日至25日波士頓世界孤兒藥物會議上展示臨床突出成績 |
|
| Mar 29, 2024, 06:33 HKT/SGT |
| Avance Clinical將在世界疫苗大會上分享最新的疫苗臨床試驗新聞，包括HIV-1研究 |
|
| Feb 28, 2024, 17:00 HKT/SGT |
| Avance Clinical執行長談論了「美國生物技術產業的綠色新苗」和一份新的CRO報告 |
|
| Jan 16, 2024, 19:00 HKT/SGT |
| 最新的分析顯示，65%的美國生技公司在尋找合適的合約研究機構（CRO）合作夥伴方面面臨困難 |
|
| May 30, 2023, 11:00 HKT/SGT |
| 2023 ASCO和BIO上的Avance Clinical：早期腫瘤治療試驗越來越複雜，對患者的需求也越來越大 |
|
| May 25, 2023, 13:05 HKT/SGT |
| Avance Clinical 加入全球健康峰會活動，以更快獲得改變生活和拯救生命的療法 |
|
| Apr 18, 2023, 11:00 HKT/SGT |
| Avance Clinical 首席執行官加入 2023 年歐洲進化峰會 全球生物製藥小組 |
|
| Jan 12, 2023, 07:00 HKT/SGT |
| Avance Clinical 慶祝GlobalReady成功 超過40家生物技術客戶進入計劃 |
|
| Oct 27, 2022, 08:00 HKT/SGT |
| Avance Clinical贊助全球Scrip獎項的中國生物製藥獎 |
|
| Sept 6, 2022, 14:00 HKT/SGT |
| Avance Clinical 宣布收購北美 CRO擴大生物技術的後期服務 |
|
| Aug 30, 2022, 06:00 HKT/SGT |
| Avance 臨床贊助商在 2022 年 Informa Pharma Intelligence Awards 中獲得年度生物技術公司獎 |
|
| Apr 19, 2022, 10:02 HKT/SGT |
| Avance Clinical進入Informa Pharma Intelligence 2022年亞太地區最佳CRO最終候選名單 |
|
| Mar 31, 2022, 15:00 HKT/SGT |
| Avance Clinical墨爾本辦公室正式啟動 |
|
| Mar 2, 2022, 15:00 HKT/SGT |
| Avance Clinical悉尼辦公室正式啟動 |
|
| Jan 19, 2022, 07:00 HKT/SGT |
| Avance Clinical在2022年生物技術展上宣佈為美國擴張進行重大私募股權投資 |
|
| Oct 19, 2021, 15:00 HKT/SGT |
| Avance Clinical臨床試驗合作申辦方XWPharma正式開啟其XW10508首次人類臨床試驗，研究快速緩解難治性抑鬱症以及慢性疼痛療法 |
|
| 更多新闻 >> |
|
|
|
